Blockchain Registration Transaction Record

Kairos Pharma Presents Breakthrough Lung Cancer Therapy Data at World Conference

Kairos Pharma presents Phase 1 data for ENV105 lung cancer therapy at World Lung Cancer Conference 2025. Breakthrough combination treatment targets drug resistance in EGFR-mutated NSCLC patients.

This development matters because lung cancer remains one of the deadliest cancers worldwide, with non-small cell lung cancer accounting for approximately 85% of all cases. Drug resistance is a major challenge in cancer treatment, often leading to treatment failure and disease progression. Kairos Pharma's ENV105 represents a novel approach that could potentially overcome this resistance mechanism, offering hope for improved survival rates and better quality of life for lung cancer patients. If successful, this therapy could transform standard cancer treatment protocols and provide new options for patients who have developed resistance to existing therapies, addressing a critical unmet medical need in oncology.